Novo Integrated Sciences, Inc.

Novo Integrated Sciences, Inc. engages in the provision of medical services. The firm offers specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, chiropodist, neurological functions, kinesiology, and dental services. Its multi-disciplinary healthcare services and protocols are directed at assessment, treatment, management, rehabilitation, and prevention through its clinics, affiliate clinics, retirement homes, and long-term facilities. The firm operates through the following business segments: healthcare services, and product manufacturing and development. The company was founded by Michael H. Rouse on November 27, 2000 and is headquartered in Bellevue, WA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Integrated Sciences, Inc. engages in the provision of medical services. The firm offers specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, chiropodist, neurological functions, kinesiology, and dental services. Its multi-disciplinary healthcare services and protocols are directed at assessment, treatment, management, rehabilitation, and prevention through its clinics, affiliate clinics, retirement homes, and long-term facilities. The firm operates through the Healthcare Services and Product Sales segments. The company was founded by Michael H. Rouse on November 27, 2000 and is headquartered in Bellevue, WA.

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results.

Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results

On Friday, Novo Integrated Sciences Inc NVOS announced it received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit (SBLC).

What's Going On With Novo Integrated Sciences Stock On Friday?

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program.

Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program

Novo Integrated Sciences is a unique nano-cap company with the potential for massive growth through game-changing, non-dilutive financing. Novo is working towards closing 3 major funding transactions, including a $70M promissory note, $78M for the monetization of gemstones expected to deliver surplus cash, and a one-billion-dollar gold-backed bond. Success in securing funding will be a true inflection point for NVOS, dramatically changing the fortunes of the company for the better.

Novo Integrated Sciences: A Coil Spring Ready To Explode

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that it has received confirmation of the issuance of a Standby Letter of Credit (“SBLC”) by HSBC for delivery by Swift MT760, as part of a program designed for monetizing SBLCs. As previously reported, the Company entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million under the SB.

Novo Integrated Sciences Receives Confirmation of Issuance of SBLC by HSBC for SBLC Leasing and Monetizing Program

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the Company's Board of Directors has approved an increase of up to $10 million maximum amount, from the previously announced up to $5 million maximum amount, for the repurchase of the Company's outstanding common stock from time to time in the open market at prevailing market prices or in privately negotiated transactions. The increased maximum amount available for purchase.

Novo Integrated Sciences' Board of Directors Approves Increase of Maximum Amount Under Stock Repurchase Program to $10 Million

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that its wholly owned Canadian subsidiary, Acenzia Inc. (“Acenzia”), has been selected by Protein Industries Canada to participate in a new project to bring new protein products with a superior nutritional amino acid profile to the global marketplace. The total project is expected to see approximately $5.4 million invested into the development, reformulation, and commerciali.

Acenzia Selected to Participate in Protein Industries Canada Program to Develop Plant Based Protein Products

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today the Company and RC Consulting Consortium Group LLC, in favor of SCP Tourbillion Monaco (“RC”), have amended the prepayment terms and conditions of the previously disclosed $70,000,000 promissory note, dated April 26, 2023 (the “RC Note”) to provide that, at any time after 12 months and no later than 60 months from the commencement of the term of the RC Note and prior to an e.

Novo Integrated Sciences and RC Consulting Consortium Group Amend $70,000,000 Promissory Note

Citizens Financial Group

NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns a long-term rating of AA- to the Pennsylvania Turnpike Commission Turnpike Revenue Bonds, Series C of 2024. KBRA additionally affirms: The long-term rating of AA- for the Commission's outstanding Turnpike Revenue Bonds The long-term rating of A+ for the Commission's outstanding Turnpike Subordinate Revenue Bonds The long-term rating of AA- for the Commission's outstanding Motor License Fund-Enhanced Turnpike Subordinate Special Revenue Bonds The Outlook f.

KBRA Assigns AA- to Pennsylvania Turnpike Commission Turnpike Revenue Bonds, Series C of 2024; Affirms Related Ratings

Novo Integrated Sciences (NASDAQ: NVOS ) stock is rocketing higher on Friday after the company said it wants to further maximize its stock repurchase program. Novo Integrated Sciences' Board of Directors is weighing options for a potential increase to the company's stock repurchase program.

Why Is Novo Integrated Sciences (NVOS) Stock Up 139% Today?

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences' Board of Directors Conducting Strategic Review to Increase Maximum Amount under Stock Repurchase Program.

Novo Integrated Sciences' Board of Directors Conducting Strategic Review to Increase Maximum Amount under Stock Repurchase Program

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Receives Confirmation of Ready, Willing and Able (RWA) Issued by HSBC for SBLC Leasing and Monetizing Program.

Novo Integrated Sciences Receives Confirmation of Ready, Willing and Able (RWA) Issued by HSBC for SBLC Leasing and Monetizing Program

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Reports Fiscal Year 2024 Second Quarter Financial Results.

Novo Integrated Sciences Reports Fiscal Year 2024 Second Quarter Financial Results

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Closes on $6,210,000 Securities Purchase Agreement.

Novo Integrated Sciences Closes on $6,210,000 Securities Purchase Agreement

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Provides Update on Certain Current Actions and Events.

Novo Integrated Sciences Provides Update on Certain Current Actions and Events

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Subsidiary, Clinical Consultants International, Signs Agreement with Futura Surgicare Pvt Ltd.

Novo Integrated Sciences Subsidiary, Clinical Consultants International, Signs Agreement with Futura Surgicare Pvt Ltd.

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Receives Limited Waiver to Securities Purchase Agreement for $70,000,000 Promissory Note.

Novo Integrated Sciences Receives Limited Waiver to Securities Purchase Agreement for $70,000,000 Promissory Note

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Appoints New President.

Novo Integrated Sciences Appoints New President

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Reports Fiscal Year 2024 First Quarter Financial Results.

Novo Integrated Sciences Reports Fiscal Year 2024 First Quarter Financial Results

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Blacksheep Trust Files Partial Assignment of $1 Billion Dollar Gold Backed Bond to Novo Integrated Sciences.

Blacksheep Trust Files Partial Assignment of $1 Billion Dollar Gold Backed Bond to Novo Integrated Sciences

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Reports 2023 Fiscal Year Financial Results.

Novo Integrated Sciences Reports 2023 Fiscal Year Financial Results

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Signs Master Collaboration Agreement with Psychocare Health Pvt. Ltd. India.

Novo Integrated Sciences Signs Master Collaboration Agreement with Psychocare Health Pvt. Ltd. India

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences' Purchase and Sale Agreement to Acquire Ophir Collection Receives Court Approval.

Novo Integrated Sciences' Purchase and Sale Agreement to Acquire Ophir Collection Receives Court Approval

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement.

Novo Integrated Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Announces Reverse Stock Split.

News for Novo Integrated Sciences, Inc. Stock (NVOS)